Quick Reference of Systemic Biologics Therapies for M-S AD

Generic (Brand)	FDA Approval Date	MOA	Indication	Patient Population	How Taken
Dupilumab (Dupixent)	2017	IL-4	M-S AD is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable	Pediatric and adult	Cutaneous injection
Tralokinumab (Adbry)	2021	IL-13			
Lebrikizumab†	Pending FDA decision (EU approved)	IL-13	Chronic M-S AD and a history of inadequate response to topical therapies or determination that the use of topical therapies was medically inadvisable		
Nemolizumab†	Phase 3	IL-31	Diagnosis of AD with inadequate pruritic response despite treatment with medium-potency (or stronger) topical therapies		

Drug	Adverse Events
Dupilumab (Dupixent)	• Most common: injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia • Serious: hypersensitivity, conjunctivitis and keratitis, eosinophilic conditions, reduction of corticosteroid dosage, arthralgia, parasitic (helminth) infections, risk of infection with live vaccine • Contraindications: Known hypersensitivity to dupilumab or any excipients in DUPIXENT
Tralokinumab (Adbry)	• Most common: upper respiratory tract infections, conjunctivitis, injection site reactions, and eosinophilia • Serious: hypersensitivity, conjunctivitis and keratitis, parasitic (helminth) infections), risk of infection with live vaccines • Contraindications: known sensitivity to tralokinumab or any excipients of Adbry
Lebrikizumab†	• Most common TEAEs reported in ≥ 2% of LEB groups: AD, conjunctivitis, nasopharyngitis, allergic conjunctivitis, COVID-19, headache, oral herpes, vaccine complication, folliculitis, dry eye, UTI, URTI, acne, arthralgia, dysmenorrhea
Nemolizumab†	• Most common TEAEs reported in ≥ 5% of pooled NEMO groups: nasopharyngitis, AD, blood creatine phosphokinase increased, contact dermatitis, influenza, urticaria, acne, cellulitis, headache, dental caries, upper respiratory tract infection, gastroenteritis

† Information in table based on clinical trial data.
Note: Resource to be updated if FDA updates are provided during activity duration.